ARMANDO ANIDO - 23 Jan 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Role
Chairman & Chief Exec. Officer, Director
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
23 Jan 2023
Net transactions value
-$21,194
Form type
4
Filing time
25 Jan 2023, 16:25:25 UTC
Previous filing
20 Jul 2022
Next filing
02 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Sale $21,194 -35,453 -5.8% $0.5978 576,235 23 Jan 2023 Direct F1
transaction ZYNE Common Stock Award $0 +250,000 +43% $0.000000 826,235 24 Jan 2023 Direct F2
holding ZYNE Common Stock 26,595 23 Jan 2023 See footnote F3
holding ZYNE Common Stock 13,297 23 Jan 2023 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F2 The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025.
F3 TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.